RecruitingNCT06093022
Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
720 participants
Start Date
Apr 1, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- \> 18 years old
- BCLM
- BCLM and extra-hepatic disease
- Any treatment
- Ability to understand and sign the informed consent
Exclusion Criteria2
- Inability to provide the informed consent
- Patient who underwent Best Supportive Care or Palliation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06093022
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location